X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA NOVARTIS NATCO PHARMA/
NOVARTIS
 
P/E (TTM) x 23.5 361.7 6.5% View Chart
P/BV x 17.8 17.8 100.0% View Chart
Dividend Yield % 0.6 1.6 39.7%  

Financials

 NATCO PHARMA   NOVARTIS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
NOVARTIS
Mar-16
NATCO PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs877982 89.3%   
Low Rs424556 76.1%   
Sales per share (Unadj.) Rs223.4252.9 88.3%  
Earnings per share (Unadj.) Rs31.162.1 50.0%  
Cash flow per share (Unadj.) Rs40.363.3 63.6%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.81.3 59.1%  
Book value per share (Unadj.) Rs219.5363.6 60.4%  
Shares outstanding (eoy) m33.0731.96 103.5%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.0 95.7%   
Avg P/E ratio x20.912.4 169.1%  
P/CF ratio (eoy) x16.112.2 132.9%  
Price / Book Value ratio x3.02.1 140.1%  
Dividend payout %16.116.1 100.0%   
Avg Mkt Cap Rs m21,50424,580 87.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m1,1281,801 62.6%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m7,3898,083 91.4%  
Other income Rs m167829 20.1%   
Total revenues Rs m7,5568,913 84.8%   
Gross profit Rs m1,793234 765.7%  
Depreciation Rs m30437 829.4%   
Interest Rs m3662 20,344.4%   
Profit before tax Rs m1,2901,025 125.8%   
Minority Interest Rs m460-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m309752 41.1%   
Profit after tax Rs m1,0271,986 51.7%  
Gross profit margin %24.32.9 837.7%  
Effective tax rate %23.973.4 32.6%   
Net profit margin %13.924.6 56.6%  
BALANCE SHEET DATA
Current assets Rs m3,68112,678 29.0%   
Current liabilities Rs m3,1232,433 128.4%   
Net working cap to sales %7.6126.7 6.0%  
Current ratio x1.25.2 22.6%  
Inventory Days Days8933 273.7%  
Debtors Days Days5922 261.0%  
Net fixed assets Rs m7,68569 11,105.8%   
Share capital Rs m331160 206.9%   
"Free" reserves Rs m6,67011,460 58.2%   
Net worth Rs m7,25911,621 62.5%   
Long term debt Rs m9550-   
Total assets Rs m11,95714,400 83.0%  
Interest coverage x4.5570.5 0.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 110.1%   
Return on assets %11.713.8 84.4%  
Return on equity %14.217.1 82.8%  
Return on capital %20.723.6 87.9%  
Exports to sales %39.40.7 5,284.1%   
Imports to sales %5.718.6 30.7%   
Exports (fob) Rs m2,90860 4,830.2%   
Imports (cif) Rs m4211,503 28.0%   
Fx inflow Rs m3,445186 1,849.4%   
Fx outflow Rs m7031,821 38.6%   
Net fx Rs m2,743-1,635 -167.8%   
CASH FLOW
From Operations Rs m1,4402,531 56.9%  
From Investments Rs m-1,089-8,270 13.2%  
From Financial Activity Rs m-353-386 91.4%  
Net Cashflow Rs m-1-6,125 0.0%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 2.0 392.0%  
FIIs % 16.6 1.6 1,039.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.5 120.9%  
Shareholders   25,395 41,647 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 23, 2018 02:31 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS